Hydroxychloroquine Shortage: What Providers and Prescribers Need to Know in 2026

Hydroxychloroquine (HCQ) has been a cornerstone of autoimmune disease management for decades. The 2020 COVID-19 demand surge created one of the most disruptive drug availability events in recent rheumatology history — and its lessons continue to influence how providers counsel and prescribe. This briefing summarizes the current availability landscape, clinical implications of supply disruptions, and practical strategies for managing hydroxychloroquine prescribing in 2026.

Current Shortage Status (2026)

As of 2026, there is no active FDA-declared national shortage of hydroxychloroquine sulfate. The 2020 shortage has been fully resolved. Generic hydroxychloroquine 200 mg tablets are manufactured by multiple U.S. market participants including Dr. Reddy's, Mylan (Viatris), Amneal, Zydus, and Rising Pharmaceuticals — providing meaningful supply redundancy compared to single-source drugs.

Clinicians should note that ASHP had previously reported manufacturer-specific back orders on certain configurations (e.g., Sandoz 500-count bottle presentations) while other presentations remained available. Proactively educating patients about alternative pharmacies and generic substitution options remains prudent clinical practice.

Clinical Implications of HCQ Supply Disruptions

The clinical stakes of hydroxychloroquine interruption are well-established in the literature:

• SLE flare risk: The Canadian Hydroxychloroquine Study Group demonstrated that withdrawing HCQ in stable SLE patients significantly increased flare risk. Even a 2-week interruption has been associated with exacerbated disease activity.
• Pregnancy implications: HCQ is considered safe during pregnancy and is recommended by ACR and EULAR guidelines for pregnant patients with SLE and RA. Interruptions carry heightened risk for pregnant patients.
• Organ protection: Long-term HCQ use has demonstrated renal protective effects in lupus nephritis and reduced cardiovascular risk across multiple longitudinal studies.
• Psychosocial impact: The 2020 shortage studies documented that patients who could not access their antimalarials experienced not only increased disease activity but also worse mental health outcomes.

Prescribing Strategies to Prevent Patient Supply Gaps

The following strategies can significantly reduce the risk of patient supply disruptions:

1. Prescribe 90-Day Supplies When Clinically Appropriate

For stable patients on maintenance HCQ therapy, a 90-day prescription provides meaningful buffer against individual pharmacy stockouts and reduces administrative burden. Most Part D plans and commercial insurers cover 90-day supplies via mail-order pharmacy, often at a lower per-dose cost for the patient.

2. Write Generic-Permissive Prescriptions

Unless there is a specific clinical reason to require brand-name Plaquenil, write prescriptions as "hydroxychloroquine sulfate 200 mg" with generic substitution permitted. Multiple FDA-approved generic manufacturers produce bioequivalent 200 mg tablets, and patients can often switch between manufacturers without clinical impact.

3. Counsel Patients on Pharmacy Flexibility

Advise patients not to rely on a single pharmacy for hydroxychloroquine. In your encounter notes or patient materials, consider recommending:

• Identifying 2-3 local pharmacies that carry the medication
• Starting refill searches 7-10 days before running out
• [@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop

4. Have a Documented Bridge Plan for High-Risk Patients

For patients with high disease activity, organ involvement, or those who are pregnant, document a contingency plan in case HCQ becomes temporarily unavailable. Consider:

• Short-term corticosteroid bridge if flare risk is high
• Alternative DMARD transition plan (methotrexate adjustment, sulfasalazine, or azathioprine depending on indication)
• Clear patient instructions on when to contact your office if they cannot locate their medication

Dosing Reminders: Weight-Based Limits and Retinopathy Risk

As a reminder for prescribers managing long-term HCQ therapy:

• Maximum recommended dose: ≤5 mg/kg/day of actual body weight (hydroxychloroquine sulfate). Doses exceeding this threshold significantly increase retinopathy risk.
• Baseline ophthalmologic exam within the first year of therapy; annual monitoring for high-risk patients (duration >5 years, renal impairment, concomitant tamoxifen).
• Dosage forms available: 200 mg tablets (most common), 100 mg, and 300 mg tablets. Most maintenance dosing uses 200 mg tablets once or twice daily.

Resources for Providers

For providers looking to help patients navigate hydroxychloroquine availability, medfinder for providers offers a solution where medfinder calls pharmacies on behalf of your patients. You can also share the patient-facing 2026 Hydroxychloroquine Shortage Update article directly with patients who have questions about availability.